We began developing the idea for our first non-invasive cancer biomarker test, Melaseq™, in 2016.
Below is a timeline of our progress and milestones.
Melanoma Genomic database created
Accepted to Melbourne Health Accelerator Spring 2017 Cohort
Geneseq Biosciences invited to participate in Australia’s first hospital ‘in-situ’ accelerator program, in association with Health Round Table. The MHx program provides innovative start-up companies with the opportunity to access the world-class Royal Melbourne Hospital health system and empowers clinicians and researchers to pursue an entrepreneurial mindset within a structured collaborative framework.
Partnership with Australian Clinical Labs
Geneseq Biosciences and Australian Clinical Labs today announced they will partner to bring the first non-invasive melanoma test to market under the trademark Melaseq™. Clinical Labs is the largest pathology provider to public hospitals in Australia, with over 90 NATA accredited laboratories and 900 collection sites nation-wide.
Third Melaseq validation study published in PLOS ONE
New research published in PLOS ONE, shows that (i) the Melaseq™ test can also be used on skin biopsy tissue, (ii) the test can also identify high/low-risk melanoma, therefore predict a patient’s length of survival and (iii) the 38 microRNAs analysed Min each sample are known to regulate a significant number of immunotherapy targets. More…